Powering the future of clinical diagnostics with trusted intelligence

Clinical diagnostics is becoming more molecular, personalized, and accessible. In May 2025, the FDA cleared the first blood test used to support the diagnosis of Alzheimer’s disease, demonstrating how biomarkers can reduce reliance on more invasive or expensive diagnostic procedures. Companion diagnostics and next-generation sequencing are also becoming increasingly important in identifying patients for targeted oncology therapies.

At the same time, laboratories are becoming more connected to healthcare and public-health data systems. CDC initiatives have more than doubled the commercial laboratory data available to public-health practitioners and expanded access across over 200 reportable conditions. Globally, WHO is promoting essential diagnostics, point-of-care testing, self-testing, and stronger national laboratory systems to improve timely access to reliable diagnostic services.

Our clinical diagnostics practice tracks commercially relevant assays, instrument platforms, regulatory pathways, laboratory networks, reimbursement changes, product launches, and competitive strategies. Clients use this intelligence to size addressable markets, evaluate test adoption, benchmark competitors, prioritize indications, plan product launches, and assess market-entry opportunities.